Giant Cell Arteritis (GCA)
GCA is a large-vessel vasculitis primarily affecting branches of the external carotid artery and the aorta. It typically presents in adults over 50 and is closely linked to polymyalgia rheumatica (PMR). Untreated GCA can cause irreversible vision loss; rapid diagnosis and high-dose steroids are critical.
Symptoms
- New-onset temporal headache, scalp tenderness
- Jaw claudication (pain while chewing)
- Visual disturbances: amaurosis fugax, diplopia, blurred vision
- Constitutional symptoms: fever, weight loss, fatigue
- PMR symptoms (shoulder/hip stiffness)
- Large-vessel involvement: arm claudication, aortic aneurysm/dissection
Diagnosis
- Elevated ESR and CRP (may be normal in rare cases)
- Temporal artery biopsy showing granulomatous inflammation with giant cells (gold standard)
- Ultrasound (“halo sign”), MRI, PET-CT for large-vessel involvement or when biopsy inconclusive
- Exclude mimics (occlusive vascular disease, other vasculitides)
Treatment & Management
Immediate Therapy
- Start high-dose glucocorticoids promptly (prednisone 40–60 mg daily) even before biopsy if high suspicion
- IV methylprednisolone for vision loss or ischemic complications
Steroid-Sparing Agents
- Tocilizumab (IL-6 inhibitor) improves remission rates and allows steroid taper
- Methotrexate or azathioprine for steroid-intolerant patients (less robust evidence)
Monitoring
- Taper steroids gradually over 12–18 months guided by symptoms and inflammatory markers
- Regular ophthalmology exams, monitor for PMR relapse
- Screen for aortic aneurysm with imaging (ultrasound/CT/MRI) at diagnosis and periodically
- Manage cardiovascular risk factors (BP, lipids) due to steroid exposure and vascular inflammation
Lifestyle & Support
- Track headaches, jaw pain, vision changes, PMR symptoms, medications, and side effects
- Calcium/vitamin D, bisphosphonates for bone protection
- Manage steroid side effects (mood changes, glucose, weight)
- Mental health support; chronic high-dose steroids impact mood and energy
Complications
- Vision loss, stroke, ischemic neuropathy
- Aortic aneurysm/dissection
- Steroid-related complications (diabetes, osteoporosis, infections)
Research & Future Directions
Investigations target IL-17/IL-12/23 pathways, B-cell depletion, and biomarkers predicting relapse to personalize treatment intensity.
Experimental & Emerging Treatments
- JAK Inhibitors: Under study for steroid-refractory GCA.
- Anti-GM-CSF Therapies: Aim to reduce vascular inflammation upstream.
- Novel Imaging Biomarkers: PET/MRI fusion and ultrasound elastography to track vascular healing.
- Digital Monitoring: Wearables tracking jaw movement and vision changes may provide early relapse warning.
Track GCA with Diagnoza.care
Protect Your Vision Proactively – Log symptoms, ESR/CRP trends, steroid taper schedule, tocilizumab injections, bone health screenings, vascular imaging, and ophthalmology visits; capture side effects; and let the AI companion remind you of dose adjustments and red-flag symptoms requiring immediate care.
Medical Disclaimer: Informational only. Work with your rheumatologist and dermatologist to confirm diagnosis and tailor biologic or small-molecule therapy.
Sources: American College of Rheumatology, National Psoriasis Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)